Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated NSCLC By Ogkologos - September 10, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Teclistamab ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide... January 14, 2022 Teen With Terminal Cancer Gives Make-A-Wish Gift To Other Kids In... December 4, 2019 Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with... November 20, 2020 The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That... March 4, 2021 Load more HOT NEWS Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... OncoArray Links Dozens of DNA Variants to Risk for Common Cancers Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... 120 years of discovery: 10 ways we’ve changed the story for...
